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indirect costs, we measured the lost days of work. However, despite
their young age, all the subjects analyzed in our study were retired.
This can be explained by the fact that our center, being a pre-heart
transplantation facility, formally selects more compromised pa-
tients. However, the analysis of their functional characteristics
(LVEF, peak VO2) highlights that the ability to work was, in fact,
preserved in some subgroups of patients. We believe that this
“black hole” has been produced by a lack of published data that has
been translated into legislative misunderstanding. Our recent
experience about patients not entered into a program of evaluation
for cardiac transplantation pointed out that the frequency of return
to work was low and essentially completely detached from clinical
and functional characteristics (1). We could have used the method
of willingness to pay; this involved the introduction of another
subjective variable, but one that should have been randomly and
homogeneously distributed between the two groups and thus not
have biased the cost analysis.
Time horizon of the analysis. The building of the model
requires the survival curves of a representative population of the
considered sample to be extrapolated to zero. The introduction of
new therapies, such as beta-blockers and antialdosteronic agents,
has so drastically modified the course of the survival curves that by
the point at which the curves reached zero, the differences would
be extremely large (2,3). Hence, we applied our analysis to a
relatively short time window. Indeed, analysis of our database of
1,062 patients puts these different temporal courses of illness into
perspective (1991–1995: cardiac deaths: 198/495 (40%); 1996–
2002: cardiac deaths: 114/567 (20%). These methodological prob-
lems were reported in the study limitations.
The utility of health states. We agree with Dr. Sendi that in
a societal perspective the time trade-off (TTO) to quantify the
utility of the patient is that attributed by the society. The question
of how to quantify this remains substantially open (4). The
EuroQoL questionnaire does not eliminate the problem of sub-
jectivity in attributing the utility of illness. Different studies have
underlined that, substantially, the EuroQoL-visual analogue scale
(VAS) has been validated with a TTO method. Moreover, VAS
valuations can be affected by social class and education of patients
(5,6). Finally, in a recent report, TTO utility scores fitted with the
usual quality-of-life measures (7).
We warmly thank Dr. Sendi for his methodological clarifica-
tions as we firmly believe that only full interchange between those
proposing, implementing, and evaluating management strategies
in public health will lead to the combination of optimal health care
and optimal use of society’s resources (8).
Soccorso Capomolla, MD
Fondazione S. Maugeri
Cardiology
Via per Montescano
Montescano, Pavia 27040
Italy
E-mail: scapomolla@fsm.it
doi:10.1016/S0735-1097(03)00334-6
REFERENCES
1. Civardi A, Capomolla S, Lupo A, et al. Rischio cardiovascolare
correlato all’attivita` lavorativa e/o fisica domiciliare in pazienti con
scompenso cardiaco cronico: analisi e validazione di una scheda di
valutazione individualizzata [Cardiovascular risk correlated to the
worker and domestic physical activity in patients with chronic heart
failure: analysis and validation of a self-administered physical activity
questionnaire]. Ital Heart J 2001;3:140S–00.
2. Packer M, Bristow M, Cohn JN, et al. The effect of carvedilol on
morbidity and mortality in patients with chronic heart failure. U.S.
Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349–
55.
3. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on
morbidity and mortality in patients with severe heart failure. Random-
ized Aldactone Evaluation Study. N Engl J Med 1999;341:709–17.
4. Dolan P, Green C. Using the person trade-off approach to examine
differences between individual and social values. Health Econ 1998;7:
307–12.
5. Dolan P, Gudex C, Kind P, et al. Valuing health states: a comparison
of methods. Health Econ 1996;15:209–31.
6. Dolan P, Gudex C, Kind P, et al. The time trade-off method: results
from a general population study. Health Econ 1996;5:141–54.
7. Melsop KA, Boothroyd DB, Hlatky MA. Quality of life and time
trade-off utility measures in patients with coronary artery disease. Am
Heart J 2003;145:36–41.
8. Steinwachs DM, Collins-Nakai RL, Cohn L, et al. The future of
cardiology: utilization and costs of care. J Am Coll Cardiol 2000;35
Suppl B:91B–8B.
Use of Spironolactone in Heart Failure
Patients Receiving Angiotensin-Converting
Enzyme Inhibitors and Beta-Blockers
We read with great interest the report by Bozkurt et al. (1) which
raises important issues related to translation of research findings
into clinical practice. This is especially important for the use of
spironolactone for patients with heart failure and left ventricular
systolic dysfunction who are already receiving a beta-blocker. The
investigators demonstrated significant dissimilarities between pa-
tients enrolled in the Randomized Aldactone Evaluation Study
(RALES) and clinical practice, which might have resulted in
increased adverse effects. However, perhaps the single most im-
portant variable, the increasing dissimilarity of which will likely
determine the future role of spironolactone in heart failure pa-
tients, is use of beta-blockers. Only 11% of the RALES partici-
pants were receiving a beta-blocker (2). The American College of
Cardiology and American Heart Association heart failure guide-
lines recommend that all stable patients with heart failure and left
ventricular systolic dysfunction should receive a beta-blocker unless
specific contraindication exists (3). The weight of evidence for use
of a beta-blocker is stronger than that for spironolactone, and it is
expected that appropriate use of beta-blocker will increase in
the future. Data from the Valsartan Heart Failure Trial (Val-
HeFT) demonstrated that extensive blockade of multiple neu-
rohormonal systems in patients with heart failure may not be
desirable and may be associated with adverse outcomes (4). In
the Val-HeFT study, among patients receiving both an
angiotensin-converting enzyme (ACE) inhibitor and a beta-
blocker at baseline, use of valsartan was associated with over
40% increase in the risk of death (p  0.009) and nearly 20%
increase in the risk of combined end point of mortality and
morbidity (p  0.10). The impact of use of spironolactone on
heart failure patients already receiving an ACE inhibitor and a
beta-blocker is currently unknown. New randomized controlled
trials should be conducted before spironolactone could be
recommended for such patients.
The study also highlighted that hasty adoption of research
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findings might result in poor quality of care as it could be the result
of a delayed adoption, as in the case with ACE inhibitors and
beta-blockers. Underutilization of evidence-based therapy has
often been associated with perceived contraindications or fears of
adverse effects (5). It is hoped that future studies would examine
underlying reasons associated with hasty and inappropriate adop-
tion of evidence-based therapy.
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